Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2011

NeuroVive and to-BBB Get €1M Boost to Stroke Therapy Collaboration

  • NeuroVive Pharmaceutical and to-BBB have each received about €500,000 from Europe’s Eureka Eurostars™ initiative to further support ongoing joint development of a treatment for stroke and other acute neurological conditions. The companies have been working together since October 2010 to combine NeuroVive’s cyclosporin A candidate with to-BBB’s G-technology® platform for delivering drugs across the blood-brain barrier.

    Swedish firm NeuroVive Pharma is focused developing cyclosporine-based mitochondrial-protecting candidates for the treatment of traumatic brain injuries, reperfusion injury in myocardial infarction, stroke, and other acute injuries. The firm’s pipeline is headed by cyclophilin-D-inhibiting cyclosporin-based drugs that protect nerve and heart cells following tramautic brain injury.

    The Phase III development-stage candidate NeuroSTAT® is a lipid emulsion formulation of cyclosporin-A designed to strengthen mitochondrial membranes by inhibiting cyclophilin-D. CicloMulsion® is the cardioprotective version of NeuroSTAT, which is in Phase III development to protect against repurfusion injury in myocardial infarction.

    Earlier this month NeuroVive and U.K. CRO Selcia inked a research collaboration agreement to develop new drugs specifically targeting mitochondrial physiology and pathophysiology for indications that could potentially span stroke, heart attack, obesity, and cancer.

    To-BBB’s core G-Technology is based on the development of liposomes coated with glutathione-conjugated PEG for delivering drugs across the blood-brain barrier. The firm says it has generated proof-of-concept data in animals demonstrating that the encapsulation technology can deliver peptides and small molecules for the treatment of brain cancer, pain, and viral encephalitis. Lead in-house candidate 2B3-101 comprises glutathione pegylated liposomal doxorubicin hydrochloride for the treatment of brain cancers. In June the firm received regulatory go-ahead in the Netherlands to start a Phase I/IIa clinical trial evaluating 2B3-101 in 40 patients with brain metastases. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »